

RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN : L24232MH2007PLC169354

October 19, 2023

То

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051 BSE Limited Corporate Relationship Department 25, P.J. Towers, Dalal Street, Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Investor Presentation

Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023.

Kindly take the same on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited RAJESH RAMESH SHIRAMBEKAR Rajesh Shirambekar Head – Legal & Company Secretary

Encl: As above





Disclaimer

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document or at this presentation shall be relied upon as a promise or representation. The Company undertake no obligation to update or revise any information or other or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the "Company"), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

2



RPG Group: One of India's fastest-growing diversified conglomerates

UNLEASH**TALENT** TOUCH**LIVES** OUT**PERFORM** AND©

RPG Group has a business history dating back to 1820 AD in banking, textiles, jute, and tea. RPG Enterprises was founded in 1979 and currently operates in various businesses in Infrastructure, Technology, Tyres, Life Sciences, and plantation industries. Formerly known as Searle India, RPG Life Sciences was started as a joint venture with G.D Searle in 1968 and was rechristened to RPG Life Sciences in 1999 with G.D Searle withdrawing its India operations.

100+ years old Business Group

KEC

EPC major in infrastructure segments like T&D, Civil, Railways, Oil & Gas CAT

One of India's leading tyre Manufacturers



\$4.4 Bn Revenue

Global Technology Consulting and IT services company

20000+ Employees

An Integrated

Pharmaceutical

company

operating in

Formulations and

Synthetic APIs

Raychem RPG

Technology Solutions company catering to energy and infrastructure



BSE Listed Companies

ARRISONS MALAYALAM LIMITED One of India's largest plantation companies producing tea,

rubber etc



RPG Life Sciences: An Integrated Pharmaceutical Company – APIs to Formulations; R&D to Manufacturing to Marketing

Leader in Immunosuppressants

RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.



RPG Life Sciences Product Portfolio: Strong 'Textbook' brands being augmented by Diligent Life Cycle Management and New Launches in Chronic and Specialty therapies




Financial Performance


6




Journey of RPG Life Sciences




Q2 FY24 Performance



H1 FY24 Performance






H1 FY24: 5 Year Trends- Key Financials

H1FY24: 5Y Trajectory of Uninterrupted Margins Expansion continues despite Market Challenges EBITDA:10.4% (FY19) to 24.3%(H1 FY24);PBT: 4.6% (FY19) to 21.4%(H1 FY24);PAT: 3.3% (FY19) to 15.9% (H1 FY24)



H1 FY24: 5 Year Trends- Key Ratios (ROCE, ROE, D/E)



An 🆇 RPG Company

12

RPG LIFE SCIENCES

H1 FY24: Business Segment-wise Performance

Business Segments	Domestic Formulations (DF)	Domestic Formulations contributed 66% to total sales of H1 FY24 • 16% sales growth driven by both Legacy and New products • Growth consistently higher than the market • New products* contribution improving consistently (currently >25%) on account of new launches in Specialty & Chronic segments and line extensions of legacy products • Salesforce productivity consistently improving (currently >5 lakhs) • Business driven by 5 Pillar strategy	171.8 H1 FY23	69 199.0 H1 FY24
APIs 15% IF 19% DF 66%	International Formulations (IF)	International Formulations contributed 19% to total sales of H1 FY24 • Robust sales growth of 15% • New Products/Customers/Markets contribution continues to improve (currently ~30%) • Business driven by 4 Pillar strategy	49.0 49.0 H1 FY23	56.3 H1 FY24
	ΑΡΙ	 API contributed 15% to total sales of H1 FY24 Growth of 7% Continuous thrust on new customer development Business driven by 3 Pillar strategy 	42.9 H1 FY23	1% 46.1 H1 FY24
An 🆇 🍞 G Company		*Launched FY19 Onwards 13	RPG L	

RPG Life Sciences ICRA Rating Reaffirmed in FY23

Long term rating reaffirmed at A Short term rating reaffirmed at A1

Outlook on long term rating has been retained as Stable

The rating reaffirmation factors:

- Strong brands in the Indian Pharmaceutical Industry
- > Considerable improvement in the operating performance on the back of
 - Improvement in sales hygiene
 - Cost rationalisation measures adopted since FY20
- > A robust capital structure and strong coverage indicators based on
 - Decline in the company's debt levels
 - Healthy cash flows
 - No major debt-funded capital expenditure (capex)
- > Expansion of product portfolio and geographical presence augur well for growth prospects

14

P2G LIFE SCIENCE

Business Strategy

15

RPG LIFE SCIENCES


Domestic Formulations (DF): Overview and Strategy

- Operating in Mass/Mass-specialty and Specialty segments
- Presence in both Acute & Chronic therapy areas
- Leading Text Book Brands Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace
- Leading player in Immunosuppressant category
- Good Customer Coverage Cardiologists, Diabetologists, Urologists, Nephrologists, Rheumatologists, Oncologists
- New Product Launches in New Category Biosimilars as well as Chronic and Specialty segments

Business Strategy: 5 Pillars

1	5 pillars o	f profitable Domestic busine	ess growth	5
Product portfolio rejuvenation by building Chronic & Specialty portfolio with new launches	Strategic brand assets building through life cycle management (new line extensions, customer segments, disease segments, etc.)	Customer coverage deepening in targeted therapies by expanding field force and deploying digital	Sales force effectiveness augmentation by competencies building and productivity enhancement initiatives	Profitability improvement by Opex control, efficient manufacturing operations, sales hygiene as well as profitable product mix

DF: Diligent implementation of 5 Pillars of Business Strategy yielding results




An 🆇 RPG Company

RPG LIFE SCIENCES

International Formulations (IF) Business: Overview and Strategy

- Strong presence in immunosuppressant segment (Azathioprine)
- Footprints across Regulated and Emerging Markets Canada, UK, Germany, France, Australia, South East Asia, Africa
- Long lasting, impeccable supply track record and business relationship with some of the leading generic players of the world
- High quality and process orientation making us a preferred partner

Business Strategy: 4 Pillars




APIs Business: Overview and Strategy

- High value, low volume, niche APIs
- Mature stable molecules
- Provides backward integration to International Formulations business
- Footprints across geographies LATAM, Germany, China, South Korea, Iran, Bangladesh, Egypt, India, etc.
- Strong customer focus long-lasting relationship with big pharma • and leading generic firms.

G LIFE SCIENCES

Business Strategy: 3 Pillars



Infrastructure & Backend Capabilities

20



Manufacturing Facilities

Formulations Unit 1, Ankleshwar	 F1 unit caters to the domestic and emerging markets Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder WHO, Kenya, Nigeria approved
Formulations Unit 2, Ankleshwar	 F2 unit caters to the regulated markets Dedicated product lines for oral dosage (capsules & tablets) Equipped to handle low RH and low temperature conditions products WHO, EUGMP (from Hamburg Health authority), Canada, Ethiopia, Kenya, Sudan, Nigeria approved
API Unit, Navi Mumbai	 MF1: Multipurpose unit catering to emerging markets including India MF2: Dedicated immunosuppressant facility catering to regulated and emerging markets including India MF3: Multipurpose unit catering to regulated and emerging markets including India WHO, TGA Australia approved & Written Confirmation (WC) received from CDSCO

An 🆇 RPG Company

s CIEN

Strong Backend Capabilities



TOR TRACK and



PG LIFE SCIENCES

Operational Highlights

23



Top 10 Operational Highlights

Comprehensive Life Cycle Management Strategy for DF Legacy products yielding results	Legacy Product Naprosyn becomes the first 50 Cr+ Brand of the Company
2 New Product portfolio across identified segments contributing healthy double-digit growth	The New Product Denosumab Sales ~5 Cr in the very first year of Launch
3 New Therapy – Rheumatology becoming formidable	The New Rheumatology Franchise grows to contributing significantly to Specialty Sales
4 Multiple Initiatives expanding Prescriber & Patient base	Medico Marketing Pyramid Digital Marketing Pyramid Disease Education
5 Revenue/Cost optimization projects driving results	Revenue Enhancement: New Products, Customers and Markets Cost Optimization: Strict Opex Control, Digitalization and AVD
6 Digitalisation & Innovation Agenda impacting key areas	"RPGServ" 3.0 grows to 9 versions; Technology upgrades eQMS, eDMS, eLMS for product Quality
7 Factories, R&D, Regulatory modernising up to support Fronten	d Key Products Inhouse transfer Modernization of both plants under execution New Products development - WIP
8 Increasing Industry Interface and Performance Recognition	4 Industry Awards Increased Traction in Investor meets and Media Interaction RPG Best Corporate Performance award
9 "Happiness" Initiatives driving Happy Performance focused Culture	Happiness Score increase from 83% (FY21)→ 84% (FY22) → 87% (FY23) Ranked #2 amongst RPG group companies
10 Headwinds Management	Diligent Management of Input Costs Increase

Digitalization Initiatives: Sales and Marketing



Digitalization Initiatives: Manufacturing and Quality Operations

Roadmap of >20 Initiatives under various stages of Implementation


	Digital Retina Scanner	Intelligent Chilling Plant Manager	IOT based AHU monitoring system	Power Management System	
	 Biometric Access with IRIS/ Retina Scanner enables consistency of electronic records and signatures Access to only qualified professionals, Batch Management, Recipe Management, Au dit logs 	 Implementation of Utility Asset Management Systems with access over IoT, supported by Customized Algorithms for Efficient Monitoring, Control & Analytics 	 Operates Pumps & Chillers according to Operating Hours to maintain equal run time Automatically change over Working pump to Standby if Pump fails during operation 	 Safe, reliable, efficient, and compliant operation of electrical distribution systems, and connected assets enabling at all times 	
Quality Functions					

e-QMS: Digital platform to track all 6 quality parameters An IPG Company **e-DMS**: Digital platform to manage manufacturing/quality documents

e-LMS: Digital platform to track training sessions on CGMP

RPG LIFE SCIENCES

People Initiatives: Building Happy Performance focussed Culture



People Initiatives: Building Happy Performance focussed Culture- Glimpses



An ��RPG Company

People Initiatives: Building Happy Performance focussed Culture- Glimpses Hello Happiness Forums: Monthly Townhall for Connect, Recognition and Camaraderie



An ��RPG Company

People Initiatives: Building Happy Performance focussed Culture- Glimpses Parivar Tyohar Utsav Shrankhla: Virtual Celebration of Festivals with Families



Awards & Recognitions

31

RPG LIFE SCIENCES

RPG Life Sciences Awarded with 'Jamnalal Bajaj Award for Fair Business Practices'





RPG Life Sciences Bagged Top Awards from IDMA



RPG LIFE SCIENCES

New Launch Naprosyn+ bags Brand Champion of the Year Award



An ��RPG Company

We are Committed to our Transformation Agenda to continue our upward growth trajectory

Revenue Growth	Profit Growth and Focus on Cashflows	Strong Governance
Building Domestic Formulations Business via the identified 5 Pillars	Continued diligent thrust on cost control measures both in Opex and COGS	All operations within the Framework of strong Corporate Governance
Building Global Business through New Products/Markets/Customers		
Formulations and API plants Modernization and Capacity expansion	Product Re-engineering	
R&D Pipeline in identified niche areas	Process Efficiencies	
New Opportunities : M&A		
]		



The Journey Ahead: Diligent work on-going on 7 Pillars to "Scale-up" business

/ Final's Identified						
1	2	3	4	5	6	7
State-of-art 个 Capacity <u>PLANTS</u>	Targeted Niche- focus <u>R&D PIPELINE</u>	Institutionalized INNOVATION	TECHNOLOGY enablement	<u>M&As</u>	Lead Therapy <u>ADJACENT</u> Spaces	Talent Development /Acquisition
 Modern, Cost-efficient; cGMP Compliant; EU/PICS/TGA etc approved Higher Capacity ~2X 	 Focused New Product Grid across 3 segments R&D Organisation strengthening 	 Institutionalizat ion of Innovation – Idea platforms, Rewards, Reviews Innovation project(s) by each Department 	 Technology Identification and adoption All Areas – Front-end, Back- end Functions 	 M&A Framework with criteria defined - Target Therapies, Brands Margin 	 Identify & explore Adjacencies in RPGLS Strength therapies 	 Org structure review & role/skill-gaps identification Talent Development Talent Acquisition in role/Skill-gaps

7 Pillars Identified



